# US 2014/0193497 A1 · Taste-masked pharmaceutical compositions containing diclofenac

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0193497 A1
- Document ID: US20140193497A1
- Status: Published application
- Kind: A1
- Application number: 14/240,008
- Filed: 2013-04-19
- Published: 2014-07-10
- Earliest claimed: 2012-04-19
- Assignees: Glatt GmbH
- Applicants: Glatt AG
- Inventors: Frédéric Gerber; Marie Guhmann; Norbert Pöllinger
- Web page: https://patentgrep.com/patent/US20140193497A1

## CPC

- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/1623: {Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/2077: {Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets}
- A61K 9/2081: {with microcapsules or coated microparticles according to A61K9/50}
- A61K 9/5026: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/5073: {having two or more different coatings optionally including drug-containing subcoatings}
- A61K 9/5078: {with drug-free core}
- A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A pharmaceutical composition is described which includes diclofenac as an active ingredient. The pharmaceutical composition further includes a (meth)acrylic polymer which has a specific solubility and/or a particular functional group in one polymer component.

## Claims

### Claim 1

A pharmaceutical composition comprising:
diclofenac as an active ingredient; and
a (meth)acrylic polymer having at least one tertiary amino group containing component.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1;
wherein said (meth)acrylic polymer is present in the pharmaceutical composition in an amount in the range of ≧1.0 to ≦20.0 wt. % based on the total weight of the pharmaceutical composition.

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1;
wherein the diclofenac has a particle size between 1 and 100 μm.

### Claim 4 (depends on 1)

The pharmaceutical composition according to claim 1;
wherein the ratio between (meth)acrylic polymer and diclofenac is between 1:20 and 1:8.

### Claim 5 (depends on 1)

The pharmaceutical composition according to claim 1;
wherein said (meth)acrylic polymer is poly(butyl methacrylate-co-(2-dimethylaminoethyl)methacrylate-co-methyl methacrylate).

### Claim 6 (depends on 5)

The pharmaceutical composition according to claim 5;
wherein the poly(butyl methacrylate-co-(2-dimethylaminoethyl)methacrylate-co-methyl methacrylate) has a ratio of butyl methacrylate to (2-dimethylaminoethyl)methacrylate to methyl methacrylate is in the range of 0.5-2:1-3:1.

### Claim 7 (depends on 1)

The pharmaceutical composition according to claim 1;
wherein said (meth)acrylic polymer has a weight average molar mass in the range of 40,000 to 54,000 g/mol.

### Claim 8 (depends on 1)

The pharmaceutical composition according to claim 1;
wherein said diclofenac is the only active ingredient in said pharmaceutical composition.

### Claim 9 (depends on 1)

The pharmaceutical composition according to claim 1, further comprising:
granules in which said diclofenac and said (meth)acrylic polymer are blended.

### Claim 10 (depends on 1)

The pharmaceutical composition according to claim 1, further comprising:
pellets with cores containing said diclofenac,
wherein said cores have a coating comprising said (meth)acrylic polymer.

### Claim 11 (depends on 9)

A tablet comprising:
the pharmaceutical composition according to claim 9.

### Claim 12 (depends on 10)

A tablet comprising:
the pharmaceutical composition according to claim 10.